Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Portfolio Pulse from Vandana Singh
Intra-Cellular Therapies Inc (NASDAQ:ITCI) announced successful topline results from Study 502, evaluating lumateperone 42 mg as an adjunctive therapy for major depressive disorder (MDD). The study met its primary and key secondary endpoints, showing significant improvements in depression severity and illness severity compared to placebo. The company plans to submit a supplemental FDA application in the second half of 2024. ITCI shares rose 10.5% following the announcement.
June 18, 2024 | 2:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies Inc (NASDAQ:ITCI) reported successful results from Study 502 for lumateperone 42 mg as an adjunctive therapy for major depressive disorder. The study met its primary and key secondary endpoints, showing significant improvements in depression severity and illness severity compared to placebo. The company plans to submit a supplemental FDA application in the second half of 2024. ITCI shares rose 10.5% following the announcement.
The successful results from Study 502 indicate that lumateperone 42 mg is effective as an adjunctive therapy for MDD, meeting both primary and key secondary endpoints. This positive outcome is likely to boost investor confidence and drive the stock price up. The planned FDA application further adds to the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100